Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137682 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 198
- Enrollment target
NCT01137682 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 198 participants.
The verdict
NCT01137682, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 198 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
Interventions
- DRUG Pasireotide
- DRUG octreotide LAR 30mg
- DRUG lanreotide ATG 120mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2010-07-19 |
| Est. Completion | 2017-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137682
The ClinicalTrials.gov registry entry for NCT01137682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pasireotide is the first listed.
NCT01137682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01137682 about?
NCT01137682 is a clinical study titled "Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly". This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
What is the current status of trial NCT01137682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 198 participants. The study started on 2010-07-19. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT01137682?
The interventions under investigation include: Pasireotide (DRUG), octreotide LAR 30mg (DRUG), lanreotide ATG 120mg (DRUG).
Who is sponsoring clinical trial NCT01137682?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.